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CERVICAL CO-TESTING FOR THE EARLY DETECTION OF 
INTRAEPITHELIAL NEOPLASIA IN HIV-POSITIVE WOMEN 
 
RACHEL O. ALADE 
 
 
 
ABSTRACT 
 
CONTEXT & OBJECTIVE: This study aimed to assess whether HIV+ women at Boston 
Medical Center had an increased likelihood of developing intraepithelial neoplastic 
changes in the up to 6 years following a normal Pap smear and negative HPV (Human 
Papillomavirus) test when compared to the general population. The development of the 
neoplastic changes was also compared in HIV+ women with positive or negative HPV 
results. 
DESIGN & SETTING: We performed a retrospective chart review of the patient records 
of HIV+ women at Boston Medical Center. 
METHODS:  HIV+ women, aged ≥ 30, screened between 2008-2010, with a normal 
cervical cytology result (Negative for Intraepithelial Lesion or Malignancy) and a 
concurrent HPV testing result and at least one subsequent cytology result were identified 
through the electronic medical record data warehouse at a single institution. These 
women were divided into two groups based on their HPV test result, either positive or 
negative. The medical records of these women were then evaluated through the end of 
2014. The primary endpoint was the diagnosis of CIN-2 or 3, and the secondary 
endpoint was the diagnosis of other high-grade anogenital dysplasia. We examined the 
distribution of outcomes with a Chi-squared test or Fischer’s test for discrete values and 
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Student t-test for continuous data. Logistic regression analysis was performed to 
evaluate the relationship between variables and control for confounders like age and 
ethnicity. The crude and adjusted Odds Ratios (OR) were calculated and presented. We 
considered p-value < 0.05 to be statistically significant. 
RESULTS: 378 HIV+ women were identified- 307 women were HPV-negative, and 71 
patients were HPV-positive at baseline. Women ranged in age from 30-81 years. HPV-
negative patients had a mean age of 47±9, and HPV-positive patients had a slightly 
higher mean age of 49±9 at time of final evaluation. A total of eight (2%) women 
developed CIN-2, and five (62.5%) of them were HPV- positive at baseline (p-value of 
0.001). Three individuals developed CIN-3, and two (66%) of them were also HPV-
positive at baseline (p-value of 0.03). 23 (6.1%) individuals received at least one 
abnormal histology result, and of these, 13 (56.5%) were HPV-positive at baseline. After 
adjusting for age and race/ethnicity, there was still a significant difference of CIN-2/3 in 
HPV-positive women when compared to the HPV-negative group (Odds Ratio: 5.64 95% 
Confidence Interval of 1.2-26.1, p<0.03). 
CONCLUSION: The results demonstrated that the likelihood of the development of CIN-
2/3 in HIV+ women with normal pap tests and a positive HPV co-test is significantly 
higher in comparison to HIV+ women with a normal pap test and a negative HPV co-test. 
Therefore, HIV+ women with negative HPV tests had a greater incidence of CIN-3 than 
the general population (0.3% compared to 0.16%). Although HIV+ women with a 
negative HPV co-test are less likely to develop CIN-2/3 than HIV+ women a positive 
HPV co-test, a negative HPV test result is not as reassuring against the development of 
CIN-2/3 in HIV+ populations as it is in the general population. 
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BACKGROUND 
 In July of 1957, Dr. George N. Papanicolaou addressed the International 
Conference of Applied Exfoliative Cytology and spoke of the importance of the 
field of exfoliative cytology as a “major contribution to the science of humanity 
(Diamantis, Magiorkinis, & Koutselin, 2014).” Dr. Papanicolaou’s life work 
established the efficacy and importance of this pathologic discipline. At the time, 
few understood the immense applicability of his work, including Dr. Papanicolaou 
himself. He ended his speech noting that, “a big part of our knowledge in 
cytology and histopathology of early cancer was connected with cervical 
cancer… [C]ytological tests... [could] provide enough material for cytologists to 
study cervical cancer pathology and enabl[e] clinicians to treat cancer… [at] 
earlier stage[s] (Diamantis, Magiorkinis, & Koutselin, 2014).” 
 Dr. Papanicolaou’s most recognizable clinical contribution is likely the 
screening test named for him- the Pap smear. In the midst of his research with 
vaginal smears, Papanicolaou fortuitously identified cancerous cells from the 
cervices of women with cervical cancer (Diamantis, Magiorkinis, & Koutselin, 
2014). This discovery prompted the idea to use an exfoliative cellular sample to 
detect cervical cancer in women not yet diagnosed (Diamantis, Magiorkinis, & 
Koutselin, 2014).  
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Figure 1: Typical Pap Smear. An exfoliative cytology sample collected from the cervix. Stained 
using hematoxylin, orange G, and eosin using the Papanicolaou method. In such smears, 
abnormalities in cell size, nucleus proportion, etc. can be detected. Cells stain different colors 
based on their keratin content.  
 
Dr. Papanicolaou’s collaboration with Dr. Herbert Traut, a physician and 
specialist in female histological preparation, resulted in the publication of The 
Atlas of Exfoliative Cytology in 1956 (Diamantis, Magiorkinis, & Koutselin, 2014). 
This exhaustive guide explicitly described this pathological method and solidified 
the applicability of exfoliative cytology in routine clinical practice, specifically in 
screening for cervical cancer (Diamantis, Magiorkinis, & Koutselin, 2014). 
 
THE CERVIX 
The cervix makes up the lower, cylindrical portion of the uterus, and 
although the cervix is continuous with the uterus, it differs histologically from it 
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(Meschner, 2013). The cervix is composed of two areas that are also 
histologically distinct- the exocervix is contiguous with the vagina and composed 
of a nonkeratinized, squamous epithelium (Meschner, 2013). The endocervix 
composed of simple columnar epithelium and many secretory glands; it is 
contiguous with the uterus (Meschner, 2013). The two histologic areas of the 
cervix meet at a junction referred to as the transformation zone (Meschner, 
2013). The transformation zone has a transient position that changes throughout 
the lifetime of a woman by the influence of estrogenic stimulation (Hamilton et al., 
2014).  
 
Figure 2: The Internal Anatomy of the Female Reproductive System. The exocervix is contiguous 
with the vagina, & the endocervix is contiguous with the uterus. 
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The work of Dr. Papanicolaou laid the foundation for our understanding of how 
hormones directly affect the cervix. Menarche, pregnancy, ovulation, 
menstruation, and menopause all affect the consistency of and secretions 
released by the cervix (Meschner, 2013). The collection of cells obtained through 
slight scraping of the surface of the cervix is known as a Pap smear (Hamilton et 
al., 2014).  
 
CERVICAL CANCER SCREENING 
Cervical specimens for cytology are obtained during a speculum exam 
and are processed for cytologic reading by cytopathology. A cervical cytology 
result can be classified as normal (i.e. Negative for Intraepithelial Lesions or 
Malignancy (NILM)) or abnormal (i.e. ASCUS, AGC, ASC-H, LGSIL, HGSIL, 
etc.), which correspond to varying degrees of severity. A numerical scale 
describes the degree of dysplasia (i.e. Cervical Intraepithelial Neoplasia (CIN) - 
1, CIN-2, & CIN-3), with higher numbers indicating more severe dysplasia. A 
cytological diagnosis of LGSIL is approximate to a diagnosis of CIN-1, and a 
diagnosis of HGSIL is approximate to a histologic diagnosis of CIN-2 or CIN-3 
(Darragh et al., 2012). A definitive diagnosis of intraepithelial neoplasia can only 
come from a histological sample. 
Providers regularly collect cytology samples to detect the presence of 
abnormal cells in the cervix. An abnormal pap smear can necessitate a 
colposcopic evaluation, during which providers examine the cervix under 
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magnification with the application of 5% acetic acid for visual changes in the 
epithelium that are suggestive of HGSIL. The provider will then take a directed 
biopsy of these suspected abnormal areas of epithelium to be processed for the 
purpose of histological diagnosis. A high-grade lesion (CIN-2+) is an indication 
for treatment by excision or ablation of the transformation zone of the cervix 
(Morantz, 2006). Treatment of CIN-2+ can prevent against the progression to 
Intraepithelial Cervical Cancer (ICC) quite effectively. The efficacy of regular Pap 
testing can be seen in the disproportionate rates of cervical cancer diagnosis and 
mortality in regions of the world that do not have well executed cervical cancer 
screening programs (World Health Organization (WHO), 2014).  
 
Figure 3: Worldwide Incidence of Cervical Cancer per 100,000 (2005) Regions with lower rates of 
regular cervical cancer screening have disproportionately higher rates of both cervical caner 
diagnosis and mortality. 
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DIAGNOSIS AND STAGING OF CIN 
Intraepithelial neoplasias are the 
direct precursors to ICC and their stage 
suggests a clinical course of action. The 
Lower Anogenital Squamous 
Terminology (LAST) Project provided 
pathologists with a repertoire of 
common terminology to use to describe 
HPV-related dysplasia of the anogenital 
region (Darragh et al., 2012). More 
Figure 4: The Progression of Cervical Dysplasia 
(2012). The epithelium of the cervix is a non-
keratinized stratified squamous tissue layer 
composed of multiple layers of pancake shaped 
cells. This tissue layer acts as a physical barrier 
against pathogens. A. Normal Squamous 
Epithelium: Normally, the cells making up this 
epithelium have a uniform appearance. Cells in 
the same stratum look similar and remain in a 
confined area. Some cellular mitosis is present, 
but remains confined to the clearly delineated 
basement membrane. B. CIN-1: Squamous cells 
remain present along with indistinctively shaped 
cells. Cells vary in size within the same stratum. 
Mitotic activity has increased and is no longer 
confined to the lowest part of the stratum. C. CIN-
3: Severe dysplasia with mitotic activity no longer 
confined any particular stratum. Cells vary in size 
and location, and the basement membrane is 
much less distinct. These structural changes 
make metastasis more likely and leave the 
underlying tissue more vulnerable to infiltration by 
pathogens. 
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important than the terminology of different stages of CIN is the clinical 
implications associated with each degree of diagnosis (Darragh et al., 2012). The 
ASCCP (American Society for Colposcopy and Cervical Pathology) 
acknowledges all three tiers of CIN, particularly in adolescents and young 
women, but in its clinical guidelines, it uses a diagnosis of CIN-3+ as its threshold 
of treatment (Darragh et al., 2012 & Saslow et al., 2012). Approximately 40% of 
women who develop CIN-2 will self-resolve within 2 years of diagnosis and will 
not require further treatment (Morantz, 2006). According to the LAST project, the 
definitive difference between CIN-1 and CIN-2 is the presence of p-16 (Darragh 
et al., 2012). Pathologists can view the p-16, a tumor suppressor protein, with the 
assistance of immunohistochemistry of hematoxylin and eosin staining 
morphology, and only CIN-2+ lesions contain p-16 (Darragh et al., 2012). For this 
reason, we included both the development of CIN-2 and CIN-3 in our analysis of 
HIV+ patients at BMC.  
 
CERVICAL CANCER 
Invasive Cervical Cancer (ICC) is the most common gynecological cancer 
in the world, and the most common type of cervical cancer, squamous cell 
neoplasia, effects the cells of the ectocervix (Hoffman et al., 2012 & Hamilton et 
al., 2014).The exposure of the transformation zone of the cervix to the vaginal 
environment can lead to the development of neoplasia (Meschner, 2013). 
Younger women have higher rates of cervical cancer diagnosis when compared 
8 
 
to older women (Hoffman et al., 2012). Collections of dysplastic, cervical cells 
precede the development of ICC. These changes are known as Cervical 
Intraepithelial Neoplasia (CIN), and are staged according to their severity (CIN-1, 
2, and 3). CIN-1 lesions often will regress on their own, while CIN-2 lesions have 
30-40% likelihood of progressing to ICC due to their genetic instability (Stanley, 
2014). 
Magnetic Resonance Imaging (MRI) tends to more accurately describe the 
extent of ICC in the uterus when compared to Computed Tomography (CT) 
scans (Seiden, 2012).  Positron Emission Tomography (PET) scans better 
demonstrate the extent of carcinoma than either a MRI or CT scan, especially in 
the pelvis (Seiden, 2012). The stage of cervical cancer dictates the best method 
of treatment. Smaller and lower-staged cervical cancers can often be treated with 
surgical treatment (Seiden, 2012). Larger and higher-staged cancers may require 
a combination of surgery with radiation and/or chemotherapy (Seiden, 2012). 
 Patients in the early stages of cervical cancer are often asymptomatic- an 
indicative cervical pap smear at this stage can detect these early dysplastic 
changes and prompt clinical intervention at a highly treatable stage (Seiden, 
2012). ICCs often have varying symptoms such as intermenstrual cycle bleeding, 
menorrhagia, the secretion odorous discharge, flank pain, or deep vein 
thrombosis due to compression of the iliac vessel (Seiden, 2012). Physical 
detection of cervical tumors is not common unless they are visible (Seiden, 
2012). 
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Figure 5: Staging of Cervical Cancer. Similarly to CIN, pathologists classify cervical cancer or ICC 
based on the degree of dysplastic cervical cell confinement. Higher numbers indicate an increase 
in disease severity. 
 
Although the prevalence of cervical cancer has decreased in the 
developed world in the past several decades, it remains one of the most common 
cancers worldwide with almost 500,000 women receiving a diagnosis and 
275,000 cervical cancer related deaths annually (et al, 2011). Approximately 50% 
of women who receive cervical cancer diagnoses in the United States have never 
previously received screening (Saslow et al., 2012). An additional 10% 
diagnosed have not received screening within the previous 5 years (Saslow et 
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al., 2012). Many of these individuals live in in medically underserved areas and 
come from lower socioeconomic statuses and, therefore, have a higher ICC 
prevalence than the general population (Saslow et al., 2012). Such populations 
present as a prime group for intervention through public health measures. The 
combination of a cervical cytology collection in conjunction with a HPV test (or a 
co-test) can predict the likelihood of a woman developing cervical cancer within a 
defined period of time (Saslow et al., 2012).   
 
HUMAN PAPILLOMA VIRUS (HPV) 
HPV, a small double stranded DNA virus, is the causative agent for a vast 
majority of cases of cervical cancer (Seiden, 2012). In the 1930s, Richard E. 
Shope discovered that a specific agent caused benign rabbit tumors (Ryan & 
Ray, 2014). The observation of HPV-induced warts established the infectious 
properties of this same virus in humans (Ryan & Ray, 2014). In 2008, German 
researcher Harald zur Hausen won a Nobel Prize in Medicine for his work 
proving HPV to be the causative agent for a majority of cervical cancers (Ryan & 
Ray, 2014). 
More than 100 strains of HPV exist, and approximately 40 strains affect 
mucosal epithelium (National Center for Immunization and Respiratory Diseases 
(NCIRD), 2014 & Hamilton et al., 2014). HPV, specifically high risk (HR) strains 
of the virus, targets epithelial squamous cells, specifically those in the 
transformation zone of the cervix and anus (Brickman & Palefsky, 2015). HR-
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HPV strains, in order of frequency, include types 16, 18, 45, 31, 33, 52, 58, and 
35 (Ramirez et al., 2011). Dysplastic changes in the morphology of these cells or 
in the histology of these tissues may become neoplastic should they remain 
untreated. Dr. Papanicolaou’s work with cervical cell morphology and staining 
has become the pathological standard for the identification of these cytological 
abnormalities (Diamantis, Magiorkinis, & Koutselin, 2014).  
 
Figure 6: Histological Representation of the Transformation Zone of the Cervix. The arrow points 
to the junction where the epithelium changes from the exocervical nonkeratinized stratified 
squamous epithelium to the endocervix’s simple columnar epithelium. This junction is highly 
susceptible to HPV infection. 
 
Despite our increasing understanding of its effects, scientists have never 
successfully isolated the HPV virus, and the exact mechanism for infection is not 
well understood (Ryan & Ray, 2014). The identification of the presence of HPV 
occurs through the detection of viral DNA (Ryan & Ray, 2014). 
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Table 1: HPV-attributable Global Cancer Incidences (2002). Cervical cancer has a direct, causal 
link to HPV, specifically to high risk strains, 16 and 18. A majority of anal cancers can also be 
attributable to HPV. For these reasons, the HPV status of a patient is imperative in the analysis of 
a patient’s risk of developing cervical or anal dysplasia. Because the HPV status of the anus and 
cervix are not directly correlated, providers should screen for HPV in each site individually. As 
seen above, many cancers of the penis, vulva/vagina, mouth, and oro-pharynx can also be 
attributed to HPV infection. 
The presence of HR-HPV in a cytological sample aids in determining a patient’s 
risk of developing dysplasia in HPV susceptible areas. HPV tests have superior 
sensitivity and positive predictive ability when compared to cytological screening 
on its own, and 99% of all cervical cancer specimens have detectable HR-HPV 
DNA (Stanley, 2014 & Ramirez et al., 2011). 
Approximately 20 million Americans currently have an HPV infection, and 
about 80% of women will have a HR-HPV infection in their lifetime (NCIRD, 
2014). However, the majority of HPV infections are detectable for less than one 
year (Schiffman & Castle, 2005). The prevalence of HR-HPV in women is highest 
in the decade following sexual debut (between the ages 15-25) and decreases to 
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5-10% in the 4th decade of life (Schiffman & Castle, 2005). HR-HPV is 
responsible for approximately 4% of all cancers in the general population of the 
U.S. (Stanley, 2014). Cervical cancer’s only known cause is Human 
Papillomavirus (HPV), and high-risk (HR) strains of the virus are responsible for 
99.9% of all cervical cancer cases (Brickman & Palefsky, 2015). Because low-
risk strains of the HPV virus cause ailments like genital warts but are not 
associated with invasive cancer, providers do not routinely screen for them. 
 
Figure 7: The Natural History of HPV Infection and Cervical Cancer. The highest rate of HPV 
infection occurs between the teenage years and early twenties, accompanying the initiation of 
sexual activity. With time, the rate of HPV infection decreases as many women self-resolve their 
infections. Approximately 10 years after initial exposure, precancer (cervical diagnoses other than 
NILM) rates peak. Approximately 10 years after first notation of these changes, cancer rates 
peak- these are likely to due to unresolved HPV infections acquired earlier in life.  
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Because of HPV’s direct link to cervical cancer, providers regularly screen for its 
presence in addition to routine exfoliative cervical cell samples. For 
immunocompromised populations, such as HIV+ women, screening for invasive 
carcinoma precursors is of particular importance. 
 
HIV VIROLOGY 
HIV is an icosahedral, retrovirus that belongs to the lentivirus subfamily 
(Fauci & Lane, 2012). Like all viruses, HIV is unable to replicate without using the 
machinery of fully functioning cells. HIV binds to the cell surface of CD4 immune 
cells and gains entrance using one or both of two co-receptors (Fauci & Lane, 
2012). Once the virus has reached the nucleus of the cell, HIV’s viral reverse 
transcriptase enzymes initiate the conversion of its RNA to DNA using the CD4 
cell’s own reverse transcriptase mechanisms (Fauci & Lane, 2012). Ultimately, 
viral DNA becomes incorporated into the host cell’s chromosome so that cell 
replicates its own DNA; it also produces increasing amounts of viral DNA (Fauci 
& Lane, 2012). 
The integration of viral DNA into the host cell’s chromosome is permitted 
by cellular activation- therefore, latent HIV infections indicate a lack of cellular 
activity shortly after infection and the inability of the viral DNA to integrate into the 
host’s chromosome (Fauci & Lane, 2012). Unlike many other viral infections 
where host survival, viral elimination, and subsequent immunity to the virus are 
invariably linked, the body never completely rids itself of all of the HIV virus 
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(Fauci & Lane, 2012). The potency of such an infection lies in its persistent and 
often undetected presence. Frequent mutations and the intracellular location of a 
majority of virions increase the virus’ ability to evade immune system detection 
(Fauci & Lane, 2012). 
CD4 cells belong to the family of T lymphocytes, a class of cells that 
mediate the body’s immune response (Fauci & Lane, 2012). The presence of 
foreign entities activates the normally quiescent immune system (Fauci & Lane, 
2012). This activation enables the replication of the HIV virus (Fauci & Lane, 
2012). The reason for the depletion of CD4 cells is not fully understood (Fauci & 
Lane, 2012). A variety of cellular abnormalities in conjunction with the presence 
of virally infected cells may make both infected and “bystander” CD4 cells targets 
for elimination by humoral and cellular components of the immune system (Fauci 
& Lane, 2012). Depleted numbers of CD4 progressively inhibits an individual’s 
ability to mount an effectual immune response (Fauci & Lane, 2012).  
For this reason, clinical staging for HIV disease is based upon CD4 
counts, with CD4 counts of ≤ 200 clinically differentiating between HIV and AIDS 
(DynaMed: HIV Infection, 2015). Lower CD4 cell levels leave individuals 
susceptible to “opportunistic infections” (OIs) such as tuberculosis, Kaposi 
sarcoma, lymphoid interstitial pneumonia, recurrent Salmonella septicemia, 
cardiovascular complications, and invasive cell carcinoma (DynaMed: HIV 
Infection, 2015 & Flexner, 2011). These “AIDS defining infections” are classically 
associated with advanced stages of the disease as demonstrated by the first 
16 
 
recognized HIV patients in the 1980s (U.S. Department of Health & Human 
Services (UDHHS), 2010). Recognition of particular ailments as those classically 
associated with HIV has also led to more targeted and rigorous screening 
practices by healthcare providers. 
 
PHARMACEUTICAL INTERVENTIONS 
The development of Highly Active Antiretroviral Therapy (HAART) 
dampened the assumption of certain death for those living with HIV/AIDS, while 
the more recent use of Combination Antiretroviral Therapy (cART) has continued 
to improve the quality and length of life for these patients (Lee et al., 2001). 
These drugs require lifelong adherence in order to consistently inhibit viral 
replication and prevent the potential and rapid development of viral resistance 
associated with inconsistent administration (Flexner, 2011). Effective HIV therapy 
ultimately inhibits or retards the replication of the HIV virus (Flexner, 2011). 
Several classes of drugs exist to target various steps in the replicative and 
distributive process of an HIV infection. Combining different therapy options can 
more effectively retard the progression of disease (Flexner, 2011).  
Providers normally begin HIV patients on three simultaneous drugs when 
beginning antiretroviral therapy- i.e. cART- with an expectation of HIV RNA levels 
decreasing to <50 copies/ml within 24 weeks post-treatment onset (Flexner, 
2011). With more potent drugs, a lower number of unique therapies can be used 
with an expectation of equivalent efficacy (Flexner, 2011). In addition to 
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pharmacological treatments, public health measures such as needle exchanges, 
consistent contraceptive use, and more comprehensive clinical oversight over 
treatments such as blood transfusions have helped to reduce the number of new 
cases of infection (Skarbinski et al., 2015). 
 
THE GLOBAL AND DOMESTIC IMPACT OF HIV 
Although scientists believe HIV originated in Africa, its impact has been 
felt globally. HIV/AIDS are assumed responsible for more than 25 million deaths 
between the late 1980s and 2009 (Fauci & Lane, 2012). The virus likely 
originated in sub-Saharan Africa, where approximately 2/3 of all those infected 
currently reside despite the region being home to only 10-11% of the entire 
world’s population (Fauci & Lane, 2012). Since 2005, the global rates of HIV 
mortality have decreased, largely due to the increased use of ARTs, and since 
2001 the number of adults newly infected with HIV in low to middle income 
countries has decreased by 30% (Murray et al., 2014 & Joint United Nations 
Programme on HIV/AIDS (UNAIDS), 2013). This has particular significance when 
considering that these countries suffer the largest impact of the disease (Fauci & 
Lane, 2012). The incidence of many HIV associated opportunistic infections (OI) 
has also decreased with the increased administration of ARTs (Stier, 2008).  
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Figure 7: Global Distribution of HIV Populations (2012). This figure shows the distribution of 
those living with HIV in different regions of the world. The bolded numbers indicate the 
estimated average of the number of individuals living in each region. 
 
In the United States, an estimated 980,000 - 1,900,000 individuals live 
with HIV/AIDS, and an estimated 48,000 individuals in North America acquire the 
disease annually (UNAIDS, 2013). Females in the United States primarily acquire 
HIV through heterosexual contact and intravenous drug use (CDC, 2015). 
Minorities and those of multi-racial descent aged 45-54 are those most likely to 
be living with an undiagnosed infection (CDC, 2012). The percentage of 
individuals in the United States receiving medical HIV care has steadily 
increased, with the likelihood of the receipt of medical care increasing with age 
(CDC, 2012).   
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HIV, HPV, & CERVICAL CANCER 
Unlike many other HIV associated OIs, the incidence of cervical cancer in 
HIV+ women has not decreased in the United States, despite an increase in the 
usage of ARTs (Stier, 2008). Before the introduction of HAART, researchers 
established the higher prevalence of intraepithelial lesions in HIV-positive 
individuals in comparison to HIV-negative populations (Piketty & Kazatchkine, 
2005). Since 1975, cervical cancer rates in the general population have 
continued to fall (Surveillance, Epidemiology, and End Results Program (SEER), 
2013). Only, 7.8 HIV-negative women in 100,000 receive a new cervical cancer 
diagnosis annually (SEER, 2013). Approximately 0.7% of the general female 
population will receive a diagnosis in her lifetime (SEER, 2013). In a recent North 
American cohort study of almost 14,000 HIV-positive women, researchers found 
a cervical cancer incidence of 26 per 100,000 (Abraham et al., 2013). Abraham 
et al. also found a clear link between older age and decreased 
immunosuppression in frequency of diagnosis of cervical cancer in this 
population (2013). 
According to the ASC (American Cancer Society), ASCCP (American 
Society for Colposcopy and Cervical Pathology), and ASCPS (American Society 
for Clinic Pathology Screening), a HIV-negative aged 30-65 with a negative co-
test, i.e. negative cervical cytology and negative HPV test (-/-), has a 0.16% 
likelihood of developing high-grade cervical changes or CIN-3+ in the subsequent 
5 years (Saslow et al., 2012). In a 2012 study of over 19,000 women, Castle et 
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al. found that a negative HPV test had a greater reassurance over a normal Pap 
test in predicting a woman’s likelihood of developing CIN-3+ in the subsequent 
10-18 years after a cervical Pap result of NILM (2012). Because co-testing has a 
greater sensitivity in detecting high-grade dysplasia than cytology alone, a -/- co-
test suggest that a woman only need receive cervical test every three years until 
she is due for her subsequent co-test (Saslow et al., 2012). Although the 
diagnosis of CIN-3+ is relatively rare, in developed countries, HIV-positive 
women still have disproportionately high rates of diagnosis compared to that of 
the general population.  
In November of 2008, Boston Medical Center (BMC) presented its 
providers with the ability to document having performed a co-test in accordance 
to the recommendations of the ASCCP. As New England’s largest safety net 
hospital as well as the home of the area’s largest HIV/AIDS program, Boston 
Medical Center provided the perfect venue in which to study the best 
preventative health practices for HIV+ female patients (Baranowski et al., 2011). 
According to previously performed work, only 53% of BMC’s HIV-infected female 
patients receive annual Pap smears (Baranowski et al., 2011). Newly diagnosed 
HIV-positive women should receive cervical Pap smears every 6 months for the 
first year and annual Pap smears thereafter (Albert Einstein College of Medicine 
of Yeshiva University (AECOMYU), 2012). Although recommendations exist for 
the frequency of co-testing for the general population, no such guidelines exist 
for HIV+ women by these national organizations (AECOMYU, 2012). Since 
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cervical cytology samples alone are not as predictive as co-testing, a distinct 
need exists for co-testing guidelines specific to this population. 
The Women’s Interagency HIV Study has provided much of the evidence-
based information available about cervical cancer in HIV+ women (Division of 
AIDS (DAIDS), 2012). From the longitudinal observation of this research cohort, 
we have learned that although HIV+ women develop CIN-3+ more frequently 
than the general population, with more frequent screening, HIV-positive and HIV-
negative women tend to develop CIN-2+ at similar rates (Massad et al., 2014). 
We also know that most HIV+ women with abnormal pap smears have a 
relatively low risk of developing CIN-2+ in the long term (Massad et al., 2013). 
From the results of these analyses and others, in 2012, Massad et al. stated that 
for newly diagnosed HIV+ women without any history of abnormal Pap smears, 
Pap testing at intervals longer than once a year is likely sufficient to detect low-
grade cervical dysplasia (2013 & Massad et al., 2012). Harris et al. performed a 
similar analysis looking for the frequency of the development of HGSIL+ in this 
same population and found no incidence of the development of these changes 
within three years in HPV-women with CD4 counts greater than 500/μL, far 
above the threshold for an AIDS diagnosis (2005). This group was reticent to 
provide any recommendations for the frequency of testing due to conflicting 
findings in concurrent literature at the time (Harris et al., 2005). Although much 
literature exists affirming the safety of intervals longer than a year between co-
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testing in HIV+ women, no overarching recommendations exist for the minimal 
interval of time that should elapse between co-tests. 
In the analysis conducted by the ASC, ASCCP, and ASCPS, researchers 
only considered CIN-3+ in their risk analysis because of its status as an 
immediate precursor to ICC (Saslow et al., 2012). These associations also 
reasoned that since a diagnosis of CIN-2 contains both CIN-1 lesions, which 
have a relatively high rate of regression, as well as CIN-3 lesions, the sole study 
of CIN-3 would allow for the issuance of more definitive recommendations 
(Saslow et al., 2012). In the general population, the analysis of CIN-3 likely 
suffices, but in an immunocompromised population, such as HIV+ women, the 
self-regression of CIN-2 is less common, and the inclusion of CIN-2+ in the 
analysis of the development of ICC will likely benefit these individuals (Massad et 
al., 2014). Additionally, according to the LAST project, the presence of p-16 in 
both CIN-2 and CIN-3 histological samples allows CIN-2 to be classified as a 
high-grade lesion (Darragh et al., 2012).  
 
RESEARCH HYPOTHESIS 
We divided our research cohort into two groups based on their HPV status 
at the study initiation. Our primary endpoint was the development of CIN-2 or 
CIN-3. We planned to compare the incidence of our primary endpoint in our study 
cohorts of HPV-positive and HPV-negative women to determine if a significant 
difference existed between them. The incidence of the development of CIN-3+ in 
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the general population after a -/- co-test is approximately 0.16% in the 
subsequent 5 years; for those who test positive for HR-HPV, the 1-4 year risk of 
the development CIN-3+ is over 10% (Saslow et al., 2012). We hypothesized that 
the overall incidence of CIN-2+ will be higher in HIV+ women when compared to 
the general population and that interval between co-testing needed in this 
population would likely be less than five years. Our secondary endpoint was the 
incidence of AIN-2+, VIN-2+, and/or VAIN-2+ since the development of these are 
also highly correlated with HPV infection. 
 
 
 
METHODS 
Eligible study participants were HIV+ women ≥30 years of age who 
received a “screening” Pap smear or co-test between November 12, 2008 and 
December 31, 2010 and at least one additional Pap smear by December 31, 
2014. For inclusion in our analysis, a patient must have received an HIV 
diagnosis before her baseline evaluation. After an expedited review by BMC’s 
Institutional Review Board (IRB), we requested pertinent data from the hospital’s 
Clinical Data Warehouse (CDW). 
From the CDW, we received the results of all anogenital Pap smears and 
histological samples taken within our specified dates. According to our 
inclusion/exclusion criteria, the minimum length of inclusion in our study was 
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three years, and the maximum duration was six years, one month, and twenty 
days. Along with the date of each appointment, we also received each patient’s 
age at the time of her appointment, her race, and her ethnicity. After receiving 
our preliminary data set, we sorted through it using the following matrix: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 9: Patient Data Sorting Matrix 
  
Screening Pap tests/co-tests include both a cervical Pap smear as well as an 
HPV test, while diagnostic Pap tests consists of only a cervical cytology 
collection, unless otherwise indicated. Patients must have had undergone a 
NILM (-) Cervical Pap test & 
Negative (-) HPV test (n=307) 
NILM (-) Cervical Pap test & 
Positive (+) HPV test (n=71) 
Baseline Cervical Pap Smear completed between 
11/8/2008—12/31/2010 with at least 1 subsequent 
Pap smear before 12/31/2014  
Boston Medical Center Patients 
Baseline Pap smear completed with 
HPV test (n=378) 
HIV+ Women ≥ 30 at the time of 
baseline appointment (n=506) 
 
25 
 
screening Pap test as their initial Pap test to qualify for inclusion. If a patient’s 
first screening Pap test fell outside of study specified parameters, we removed all 
of her information from our analysis. We verified HIV status through provider 
documentation by ICD-9 code, CD4 counts, a history of HIV pertinent blood work, 
a medication list including HAARTs or cARTs, or provider notes stating a 
patient’s HIV status. If no explicit date for HIV diagnosis was given, we used the 
first date of HIV associated prescription as our diagnosis date. 
Over the course of our analysis, we retained a master list that contained 
each study subject’s study ID as well as her Medical Record Number (MRN). We 
did not request a completely de-identified data set from the CDW due to the 
longitudinal nature of our study, during which we followed the medical history of 
many different individuals over the course of multiple appointments. We 
calculated the interval by subtracting the date of first appointment from the date 
of her final appointment. We stored all of our data, both coded and uncoded, on 
BMC’s network drive which is secured and encoded by BMC’s informational 
technology department. Both patient data sets were stored in separate, password 
protected documents. Only HIPAA certified individuals had access to patient 
data. As a retrospective chart review, we did not have any direct contact with any 
of the study participants. 
 
DATA ANALYSIS 
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After receiving our initial data, we removed all unrelated information, 
including all non-anogenital related cytology results, all vaginal Pap smear 
results, and all patient data collected before her qualifying screening Pap smear. 
All patients with an initial cervical cytology result other than NILM were also 
excluded. Should a patient have had consistent -/- co-testing results for the 
duration of their time observed, we only retained the dates of her baseline 
appointment and her final appointment to account for the duration of time her 
HPV status remained consistent. For patients whose HPV status did not remain 
consistent, we followed her until her first change in status was noted. We also 
noted all first diagnoses of AIN-2+, VAIN-2+, VIN-2+, and CIN-2+ for each 
patient. For patients with intraepithelial neoplasia diagnoses occurring on 
separate dates, we recoded the diagnoses as occurring on the same date, as we 
only had an interest in incidence of our primary and secondary outcomes.  
 
STATISTICAL ANALYSIS 
To conduct our statistical analysis, we used SAS (Version 9.4, SAS 
Institute, Inc., Carry, NC) to compare our two cohorts of HIV+ women based on 
their baseline HPV status: those with negative cervical cytology and negative 
HPV test results (-/-) and those with negative cervical cytology and positive HPV 
test results (-/+). Within each of these groups, we observed the incidence of our 
primary outcome (CIN-2+) and our secondary outcome (VIN-2+, VAIN-2+, and/or 
AIN-2+). We examined the distribution of outcomes with a Chi-squared test or 
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Fischer’s Exact test for discrete values, Student t-test, and Wilcoxon rank sum 
test for continuous data such as age. To adjust for the baseline characteristics of 
study subjects, we used a multivariate, logistic regression analysis as well as an 
adjusted Odds Ratio (OR) for HPV tests. We considered a p-value of less than 
0.05 as statistically significant. 
 
 
RESULTS 
 
 
We had total study population of 378 HIV+ women. At the commencement 
of our analysis, all patients had a normal cervical Pap smear result of NILM. 
Table 2 shows the baseline characteristics of these patients. Participants ranged 
in age from 30-81 years. African American/Black females overwhelmingly made 
up the largest racial cohort, making up 73.5% of all enrolled women. The women 
we observed received co-testing exams on dates ranging from 11/12/2008 until 
12/23/2014 and were followed for a mean time of 37±18 months. HPV-negative 
patients had a mean age of 43.9, and HPV-positive patients had a slightly higher 
mean age of 47.2 at the time of their baseline appointment. 
 A total of n=72 (19.1%) had abnormal cytology results. If a visual exam 
indicated the need for a biopsy, a provider could take one at his or her discretion. 
In our data analysis we only took note of histological samples that received an 
intraepithelial neoplasia diagnosis. N=23 (6.1%) participants had a histological 
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sample taken that yielded a diagnosis of intraepithelial neoplasia- of these, n=13 
(56.5%) of those who had biopsies taken tested HPV-positive at baseline. N=19 
(5%) individuals had an abnormal cytology result, an intraepithelial neoplasia 
diagnosis, as well as a positive HPV test.  
Table 2: BASELINE PATIENT DEMOGRAPHIC INFORMATION BY HPV 
STATUS 
 
* Patients could identify ethnically as HISPANIC/LATINA as well as with a 
 racial group 
+Percentage based on number of individuals in HPV cohort 
€ Chi-square test/Fischer Exact calculated value 
 
The HPV cohorts differed significantly with respect to age at the initial visit but did 
not differ significantly in race/ethnicity. There was no interaction between HPV 
status and covariates (age, race/ethnicity) which made such an analysis 
plausible. The overall model for Logistic regression was significant with a p-value 
of p=0.0001. 
We followed our patient cohort based on HPV status at study initiation. At 
the time their final Pap evaluation, HPV-negative patients had a mean age of 
PARTICIPANTS (n= 378) 
 HPV-Negative 
(n= 307) 
HPV- Positive 
(n=71) 
p-value 
Age (Mean ± Standard 
Deviation) 
44±9 47±9 0.005€ 
Race* 
Black 225 (73.3%)+ 53 (74.7%)+ 0.93€ 
Hispanic/Latina 34 (11.1%)+ 9 (12.7%)+ 0.93€ 
White 33 (10.8%)+ 7 (9.86%)+ 0.93€ 
Other 15 (4.9%)+ 2 (2.8%)+ 0.93€ 
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47±9, and HPV-positive patients had a mean age of 49±9. Figure 10 shows the 
age distribution of HPV-negative and positive patients at the time of their final 
appointment. A total of n=3 women developed CIN-3; of these, n=1 was HPV-
negative at baseline and n=2 (2.8% of 71) were HPV-positive at baseline. N=13 
(3.4%) individuals developed our secondary endpoint, and of these, 61.5% of 
them were HPV-positive at baseline. 
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Figure 10: Age Distribution at time of Final Evaluation by HPV Status
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Table 3: INCIDENCE OF PATIENT OUTCOMES BY HPV STATUS 
 
HPV- Negative 
(n=307) 
HPV-Positive 
(n=71) 
p-value 
Final NILM Cytology 265 (86.3%) 41 (57.7%) 0.0001€ 
Final Abnormal 
Cytology 
41 (13.4%) 25 (35.2%) 0.0001€ 
Final 
Cytology 
Diagnosis 
AGC 2 (0.7%)* 1 (1.5%)** <0.0001€ 
ASCUS 30 (9.8%)* 11 (16.4%)** <0.0001€ 
HGSIL 2 (0.7%)* 3 (4.5%)** <0.0001€ 
LGSIL 7 (2.3%)* 11 (16.4%)** <0.0001€ 
NILM 265 (82.04%)* 41 (61.2%)** <0.0001€ 
Primary 
Outcome 
CIN-2 3 (1%) 5 (2.1%)** 0.001€ 
CIN-3 1 (0.3%) 2 (0.5%) 0.03€ 
Secondary 
Outcome 
AIN-2 2 (0.7%)* 3 (4.2%)* 0.5€ 
AIN-3 4 (1.3%)&* 2 (2.8%)* 0.3€ 
VAIN-2 0 0 N/A 
VAIN-3 0 0 N/A 
VIN-2 0 1 (1.4%) 0.2€ 
VIN-3 0 1 (1.4%) 0.2€ 
* Percentage based on number of individuals in HPV cohort 
€ Chi-square test/Fischer Exact 
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For all categories of abnormal cytology diagnosis, women with an initial, positive, 
HPV status had a significantly higher rate of developing these dysplasias than 
women with negative HPV status. 1% (or 4/307) HPV-negative women versus 
10% (or 7/71) HPV-positive women developed our primary endpoing. The 
development of CIN-3, the immediate precursor to ICC, also showed a 
statistically significant difference between HPV-negative and HPV-positive 
women.  
Table 4: SUMMARY OF PRIMARY & SECONDARY OUTCOMES  
Outcome Negative (N=307) Positive (N=71) 
Adjusted 
OR 
p-value 
CIN-2 3 (1%) 5 (2.1%) 7.8 >0.008 
CIN-3 1 (0.3%) 2 (0.5%) 14.8 >0.05 
Abnormal 
Histology 
10 (3.3%) 13 (18.3%) 7 0.0001€ 
€LogRank Test 
 
Our data indicates a strong association between HPV status and the 
development of abnormal histology. This is based on a both, crude and adjusted 
logistic model. The development of CIN-2 had a crude odds ratio of 7.8. After 
adjusting for age and race /ethnicity, the effect of HPV status in the development 
of CIN-3 was stronger (OR = 14.8, p<0.05). Being ethnically Hispanic was a not 
significant (OR = 1.8, p<0.3855), however women who racially identified as 
Hispanic have almost double the risk of developing CIN-2/3. Age was also not 
significant (OR=0.97 p<0.3913).  
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When we collapsed all abnormal histology results, including CIN-2/3, AIN-
2/3, VIN-2/3, into one dichotomous variable, we obtained similar results. In the 
crude analysis, there is a significant increase in overall abnormal histology in our 
HPV-positive cohort compared to the HPV-negative cohort (OR = 6.7, p<0.0001). 
The effect of HPV status at baseline persisted after adjusting for age and 
race/ethnicity (OR = 7, p<0.0001). Being of Hispanic ethnic descent was of 
borderline significance (OR = 2.7, p<0.0635) indicating that women of Hispanic 
descent have almost three times higher risk developing abnormal cytology. Age 
was not a significant risk factor (OR=0.97 p<0.3151). Our survival/time to 
outcome analysis indicated that HPV-positive women developed histological 
abnormalities at a higher rate than those with initial HPV-negative test results.  
 
 
DISCUSSION 
This study aimed to determine the likelihood of HIV+ women with normal 
Pap smears and negative HPV (-/-) co-tests developing CIN-2+ in the 
subsequent 3-6 years. For HIV-negative women, a negative co-test indicates 
0.16% likelihood of developing CIN-3+ in the subsequent 5 years (Saslow et al., 
2012). We hypothesized that the incidence of the development of CIN-3+ would 
be greater than 0.16% in our population. We also wanted to compare the 
incidence of CIN-2+ in our HPV-negative and HPV-positive cohorts.  
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From our data analysis, we determined that HPV-positive women had a 
higher risk of developing CIN-2 or CIN-3 within 37 months of receiving an NILM 
Pap smear result in comparison with HPV-negative women. The probability of 
developing CIN-2+ within 6 years for women with a negative co-test result in our 
patient cohort was 1%, and HPV-positive women had a 10% chance of 
developing intraepithelial lesions in the same time period. HPV-positive women 
also had a higher risk of receiving a diagnosis of any intraepithelial neoplasia in 
the 6 years following a normal cytology, with a risk of 18% compared to their 
HPV-negative counterparts who had only a 4% chance of developing these 
abnormal changes. From our analysis, we can safely conclude that an HIV+ 
woman’s greatest predictor of the development of abnormal cervical changes is 
her HPV status. Based on the results of this analysis, we would suggest that 
HIV+ women with normal Pap smears and negative HPV status receive 
screening minimally every 3 years. HPV-infected HIV+ women should receive 
screening more frequently, and the currently guidelines of annual Pap screening 
are likely sufficient.  
 Massad et al, observed 4% and 5% of their WIHS derived study 
population developing CIN-2 and CIN-3, respectively (2014). We had a 
considerably smaller research cohort than their study, we observed an incidence 
of CIN-2 and CIN-3 lower than that observed in Massad et al.’s HIV-positive 
cohort. Institution specific screening frequency, well-controlled viral levels, and a 
variety of other factors could account for the lower numbers of CIN-2+ seen. As 
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noted by numerous other studies, well-controlled viral loads and higher CD4 
counts significantly contribute to a HIV+ woman’s ability to clear an HPV infection 
(Harris et al., 2005 & Massad et al., 2014). To draw more definitive conclusions, 
we would need to conduct further analysis on some of the more specific 
characteristics of our study population. We did see a definitive correlation 
between HPV status and the frequency of abnormal cytology diagnoses as well 
as histologically demonstrable neoplasias. Also, in comparison to Figure 17, our 
study participants received precancerous diagnoses almost about a decade later 
than their HIV-negative counterparts. This could indicate that their intraepithelial 
lesions were not due to latent, long-standing infections but, rather, were from 
recently acquired infections. 
Our results align well with the current research that says that primary HR-
HPV screening is quite proficient in predicting a patient’s likelihood of developing 
dysplasia, particularly in individuals >25 years of age (Warner et al., 2015). 
Although the use of co-testing cervical Pap smears is the method most 
emphasized by major guidelines, from this analysis and others, we can begin to 
strongly advocate for HPV testing alone as a valid screening alternative (Warner 
et al., 2015). In their longitudinal study of over 19,000 women, Castle et al. found 
that the detection of HR-HPV, specifically strains 16 and 18, could accurately 
predict the development of CIN-3+ up to 18 years in the future (2012). Our 
results also align well with the ASC, ASCCP, and ASCPS’ decision not to include 
CIN-2 as a high-grade dysplasia. From our results, it appears as if many women 
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resolved their CIN-2 dysplasias, but without more specific, longitudinal analysis, 
we cannot definitively say this was true. 
 
LIMITATIONS 
Although we observed some significant results, our ability to broadly apply 
our knowledge to a larger population is restricted by a few limitations. First, we 
only followed patients up until her first change in cytology or HPV status. Her 
resolution of an HPV infection could have provided us with valuable information 
about not simply the incidence of our endpoints, but also of rate of self-resolution 
in our population. To establish a more definitive correlation between the 
diagnosis CIN-2/3 and negative co-test results, we would need to follow this 
patient population at BMC for a longer period of time. Ideally, we would follow our 
BMC cohort until their risk of the development of CIN-2/3 has decreased, after 
the age of 65 (Saslow et al., 2012).  
Also, a pathologist can only give a definitive CIN-2/3 diagnosis through 
analysis of a histological sample, which providers only take if indicated. Some 
study subjects could have had a diagnosis of CIN-2+ during the time over which 
we observed them, but without a histological sample, we could not have 
confirmed this. Because not every patient had a biopsy taken, we cannot have 
claimed to fully have captured all possible instances of our primary or secondary 
endpoints. Additionally, we had a few missing points in our data set, which is 
fairly common in retrospective studies where patient information is often lost to 
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follow-up. Although the implications of the results of this data analysis are 
important to patients at BMC, and possibly other Boston area hospitals, they are 
not generalizable to other HIV populations. The generalizability of our results is 
limited by a relatively small sample size, the extraction of data from a specific 
and localized patient population, and the relatively short period of time over 
which each individual patient was followed.  
 
FUTURE DIRECTIONS 
Although these preliminary findings are interesting, we believe that 
additional, productive analysis could be performed using this data. From 
academic literature, we know that lower CD4 counts decrease an individual’s 
ability to clear an HPV infection or self-resolve dysplasia (Massad et al., 2012). 
Noting the CD4 counts associated with each incidence of abnormal biopsy would 
allow us to better see that correlation within our own patient cohort. It might also 
prove fruitful to consider other diagnoses of anogenital dysplasia within a 
specified window of time before or after CIN-2/3 detection to detect parallels in 
the staging and incidence of concurrent dysplasias.  
A variety of factors affect the development of high grade dysplasia in the 
anogenital region. We did not analyze the time intervals between the resolution 
of a positive HPV status to a negative status or vice versa. Considering the fact 
that we had so few individuals with CIN-2+, this information could provide 
additional information to reinforce our recommendation for the interval of time 
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between screenings allowable.  It would also be beneficial to compare our cohort 
to a matched group, ideally HIV-negative BMC patients. Knowing if HIV-negative 
women at our institution had comparable incidence of CIN-3+ to that predicted by 
the ASC, ASCCP, and ASCPS would let us know if the results of our institution 
could be skewed.  
 Future research could also analyze the impact of previous diagnoses of 
CIN-2+, longitudinal observation of individuals with abnormal Pap smears, length 
of time between an abnormal Pap result and the development of CIN, and a 
patient’s history of treatment for dysplasia. These analyses would include the 
observation of similar populations at other area hospitals and ultimately at 
institutions in other parts of the nation. This analysis was limited by time, funding, 
and scope but with additional resources, we could perform additional data 
analysis involving other medical institutions in Boston and beyond. 
We only looked at the development of CIN-2/3 following a participant’s 
baseline co-testing. We did not include the data of patients who had CIN 
diagnoses prior to 11/18/2008 or prior to their qualifying co-test. A previous 
diagnosis of CIN-2/3 might itself be the best predictor of the development of CIN-
2/3 (Katki et al., 2013). Additionally, guidelines by previously mentioned 
organizations vary based on an individual’s history of CIN-2+ (Saslow et al., 
2012). Knowing of our subjects’ medical history of CIN-2+, we might have also 
been able to analyze if successful treatment or management of such lesions 
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provided protection against the development or progression of intraepithelial 
neoplasias in the future. 
 
 
 
 
 
 
 
CONCLUSION 
 
In their article The Diagnosis of Uterine Cancer by the Vaginal Pap Smear, 
Dr.s Papanicolaou and Traut wrote, “In the struggle to control cancer, knowledge 
of the many phases of the disease process as well as the ability to recognize it in 
its early stages has been so inadequate that the development of any new method 
of approach to the problem is of [utmost] importance. This is particularly true of 
malignant disease of the uterus (Papanicolaou & Traut, 1943).” The work of Dr. 
Papanicolaou and his collaborators addressed the desperate need for the early 
detection of ICC and continues to impact the lives of millions around the world 
today. Thanks to the discovery of the predictive ability of exofoliative cytology, no 
reason exists for cervical cancer to remain a major cause of mortality in the 
general population nor as an AIDS- defining malignancy for HIV+ women. The 
next step in the improving the quality of life for those living with HIV involves the 
informed application of evidence-based screening practices in countries where 
cervical cancer remains a significant contributor to female mortality (Partridge et 
al., 2014).   
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More than 530,000 women globally receive cervical cancer diagnoses 
annually, and 270,000 will die from the effects of this invasive carcinoma (WHO, 
2013). More than 85% of these deaths occur in low to middle income countries 
(WHO, 2013). In response to these rates, the WHO has outlined a three tiered 
approach to preventing and minimizing the effects of cervical cancer. Primary 
prevention involves education and the vaccination of females aged 9-13; 
secondary prevention involves co-testing of women >30 years of age, and tertiary 
treatment involves the treatment of invasive carcinoma (WHO, 2013).  
The United States provides an excellent example of the efficacy of these 
interventions. According to Hariri et al., between 2008 and 2012, the percentage 
of CIN-2+ diagnoses related to HR-HPV decreased from 53.6% to 28.4% in 
women who only received one HPV vaccination dose (2015). With more 
consistent screening practices, cervical cancer has moved from being the second 
most common cancer in women to being the 21st most common cancer 
accounting for only 0.7% of all cancers with death rates of only 2.3 per 100,000 
in the United States (Howlander et al., 2014). Such progress in primary and 
secondary prevention over the course of a few decades demonstrates the distinct 
possibility of essentially eliminating cervical cancer as a major killer of women 
worldwide. In immunocompromised populations, the aforementioned 
interventions could effectually eliminate cervical cancer as an HIV/AIDS 
associated OI in a time period shorter than many of us may have ever thought 
possible. 
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